<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d48" origId="Bortezomib"><sentence id="DrugDDI.d48.s0" origId="s0" text="No formal drug interaction studies have been conducted with VELCADE."><entity charOffset="60-67" id="DrugDDI.d48.s0.e0" origId="s0.p4" text="VELCADE" type="drug"/><negationtags>&lt;xcope&gt;&lt;cue&gt;No&lt;/cue&gt; formal drug interaction studies have been conducted with VELCADE&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d48.s1" origId="s1" text="In vitro studies with human liver microsomes indicate that bortezomib is primarily a substrate for cytochrome P450 3A4, 2C19, and 1A2."><entity charOffset="59-69" id="DrugDDI.d48.s1.e0" origId="s1.p8" text="bortezomib" type="drug"/><entity charOffset="99-118" id="DrugDDI.d48.s1.e1" origId="s1.p11" text="cytochrome P450 3A4" type="drug"/><pair e1="DrugDDI.d48.s1.e0" e2="DrugDDI.d48.s1.e1" id="DrugDDI.d48.s1.p0" interaction="false"/></sentence><sentence id="DrugDDI.d48.s2" origId="s2" text="Patients who are concomitantly receiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy ."><entity charOffset="41-48" id="DrugDDI.d48.s2.e0" origId="s2.p20" text="VELCADE" type="drug"/><entity charOffset="53-58" id="DrugDDI.d48.s2.e1" origId="s2.p22" text="drugs" type="drug"/><entity charOffset="94-113" id="DrugDDI.d48.s2.e2" origId="s2.p28" text="cytochrome P450 3A4" type="drug"/><pair e1="DrugDDI.d48.s2.e0" e2="DrugDDI.d48.s2.e1" id="DrugDDI.d48.s2.p0" interaction="false"/><pair e1="DrugDDI.d48.s2.e0" e2="DrugDDI.d48.s2.e2" id="DrugDDI.d48.s2.p1" interaction="false"/><pair e1="DrugDDI.d48.s2.e1" e2="DrugDDI.d48.s2.e2" id="DrugDDI.d48.s2.p2" interaction="false"/></sentence><sentence id="DrugDDI.d48.s3" origId="s3" text="During clinical trials, hypoglycemia and hyperglycemia were reported in diabetic patients receiving oral hypoglycemics."><entity charOffset="100-118" id="DrugDDI.d48.s3.e0" origId="s3.p46" text="oral hypoglycemics" type="drug"/></sentence><sentence id="DrugDDI.d48.s4" origId="s4" text="Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication."><entity charOffset="17-36" id="DrugDDI.d48.s4.e0" origId="s4.p48" text="antidiabetic agents" type="drug"/><entity charOffset="47-54" id="DrugDDI.d48.s4.e1" origId="s4.p50" text="VELCADE" type="drug"/><entity charOffset="160-172" id="DrugDDI.d48.s4.e2" origId="s4.p58" text="antidiabetic" type="drug"/><pair e1="DrugDDI.d48.s4.e0" e2="DrugDDI.d48.s4.e1" id="DrugDDI.d48.s4.p0" interaction="false"/><pair e1="DrugDDI.d48.s4.e0" e2="DrugDDI.d48.s4.e2" id="DrugDDI.d48.s4.p1" interaction="false"/><pair e1="DrugDDI.d48.s4.e1" e2="DrugDDI.d48.s4.e2" id="DrugDDI.d48.s4.p2" interaction="false"/></sentence><sentence id="DrugDDI.d48.s5" origId="s5" text="Drug Laboratory Test Interactions None known."/></document>